Immunotherapy and Personalized Medicine for Ovarian Cancer Patients
Precision medicine will change the paradigm of cancer treatment. The only kind of treatment that has proven effective in later stage cancer with durable results is combination treatments that include immune therapy. However, identifying the successful treatment combination is challenging due to the low mutation frequency in this cancer and the variability observed patient to patient. OvaCure's portfolio projects contribute to almost all the immunotherapeutic approaches. With that synergetic approach, OvaCure strives to provide ovarian cancer patients with the best chance of survival.
The 1st Science Symposium is presented by OvaCure as our contribution to the International Ovarian Cancer Month. The goal of the Symposium is to bring together patients, foundations, philanthropists and members of the scientific, healthcare, pharmaceutical and precision medicine community; not only to increase disease awareness but to provide an overview of scientific advancement and describe the goals and achievements of some of our projects.
OvaCure is a Danish not-for-profit organization, also recognized as 501(c)(3) status in the USA, which strives to combine international efforts for curing ovarian cancer. In 4 years, OvaCure has started 5 ground-breaking projects and has 2 more in the pipeline - all of which have potential to cure and would not have existed otherwise. OvaCure also focuses on making a positive impression on society by promoting disease awareness through public outreach.
17:00-18:00 Networking and light refreshments
18:00-18:10 Welcome by Kristin Parello-Plesner, OvaCure Strategic Director
18:10-18:30 Prof. Inge Marie Svane, Chief Medical Officer, and Head of the Center for Cancer Immunotherapy, Herlev Hospital
“OvaCure T-cell Infusion Project – Where are we today and where are we heading?”
18:30-18:50 Dr. Mansoor Raza Mirza, Medical Director NSGO-CTU, Chief Oncologist at the Department of Oncology, Rigshospitalet
“OvaCure Tumour-Match Project. Combination of two breakthroughs in cancer: immune therapy with a next-generation patient selection – How could it benefits patients?”
18:50 Networking opportunity
Symbion, Fruebjergvej 3
OvaCure - Curing Ovarian Cancer Together